Compare FBIZ & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | ALT |
|---|---|---|
| Founded | 1909 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.2M | 421.5M |
| IPO Year | 2012 | 2005 |
| Metric | FBIZ | ALT |
|---|---|---|
| Price | $56.13 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $66.00 | $17.67 |
| AVG Volume (30 Days) | 20.1K | ★ 2.7M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | 14.23 | ★ 25.37 |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $15.69 | N/A |
| Revenue Next Year | $8.47 | N/A |
| P/E Ratio | $39.88 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $45.90 | $2.56 |
| 52 Week High | $60.54 | $7.73 |
| Indicator | FBIZ | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 42.25 |
| Support Level | $53.68 | $2.72 |
| Resistance Level | $59.02 | $4.19 |
| Average True Range (ATR) | 1.24 | 0.12 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 49.89 | 30.49 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.